Health Care & Life Sciences » Pharmaceuticals | Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Madrigal Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
American Funds Small Cap World Fund
789,647
5.14%
789,647
0.5%
06/30/2018
SPDR S&P Biotech ETF
246,749
1.61%
636
1.01%
09/06/2018
T Rowe Price Health Sciences Fund
235,233
1.53%
235,233
0.44%
06/30/2018
Vanguard Total Stock Market Index Fund
209,285
1.36%
230
0.01%
07/31/2018
iShares Russell 2000 ETF
121,494
0.79%
-66
0.06%
09/06/2018
Vanguard Extended Market Index Fund
109,114
0.71%
1,400
0.04%
07/31/2018
Prudential Jennison Health Sciences Fund
98,149
0.64%
0
0.92%
07/31/2018
85,660
0.56%
-7,160
0.94%
06/30/2018
T Rowe Price Mid Cap Growth Fund
75,000
0.49%
75,000
0.06%
06/30/2018
iShares Russell 2000 Growth ETF
56,308
0.37%
0
0.12%
09/06/2018

About Madrigal Pharmaceuticals

View Profile
Address
200 Barr Harbor Drive
West Conshohocken Pennsylvania 19428
United States
Employees -
Website http://www.madrigalpharma.com
Updated 07/08/2019
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.